CO2022008652A2 - Derivados carboxi con propiedades antiinflamatorias - Google Patents

Derivados carboxi con propiedades antiinflamatorias

Info

Publication number
CO2022008652A2
CO2022008652A2 CONC2022/0008652A CO2022008652A CO2022008652A2 CO 2022008652 A2 CO2022008652 A2 CO 2022008652A2 CO 2022008652 A CO2022008652 A CO 2022008652A CO 2022008652 A2 CO2022008652 A2 CO 2022008652A2
Authority
CO
Colombia
Prior art keywords
inflammatory properties
carboxy derivatives
carboxy
derivatives
inflammatory
Prior art date
Application number
CONC2022/0008652A
Other languages
English (en)
Spanish (es)
Inventor
Michael Liam Cooke
David Cousin
Matthew Colin Thor Fyfe
Thomas Michael Waugh
Saleh Ahmed
Simone Alessio De
Barry John Teobald
Original Assignee
Sitryx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sitryx Therapeutics Ltd filed Critical Sitryx Therapeutics Ltd
Publication of CO2022008652A2 publication Critical patent/CO2022008652A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CONC2022/0008652A 2019-12-23 2022-06-21 Derivados carboxi con propiedades antiinflamatorias CO2022008652A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19219531 2019-12-23
EP20162545 2020-03-11
EP20189623 2020-08-05
EP20205768 2020-11-04
PCT/GB2020/053357 WO2021130492A1 (en) 2019-12-23 2020-12-23 Carboxy derivatives with antiinflammatory properties

Publications (1)

Publication Number Publication Date
CO2022008652A2 true CO2022008652A2 (es) 2022-07-19

Family

ID=74104118

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0008652A CO2022008652A2 (es) 2019-12-23 2022-06-21 Derivados carboxi con propiedades antiinflamatorias

Country Status (29)

Country Link
EP (2) EP4081511B3 (https=)
JP (2) JP7679384B2 (https=)
KR (1) KR20220119425A (https=)
CN (1) CN115066418B (https=)
AU (1) AU2020412853A1 (https=)
BR (1) BR112022011933A2 (https=)
CA (2) CA3161424C (https=)
CL (1) CL2022001722A1 (https=)
CO (1) CO2022008652A2 (https=)
CR (1) CR20220300A (https=)
DK (1) DK4081511T3 (https=)
EC (1) ECSP22049370A (https=)
ES (1) ES2987014T3 (https=)
FI (1) FI4081511T3 (https=)
HR (1) HRP20241378T1 (https=)
HU (1) HUE068571T2 (https=)
IL (1) IL293982B2 (https=)
JO (1) JOP20220162A1 (https=)
LT (1) LT4081511T (https=)
MA (1) MA58170B1 (https=)
MD (1) MD4081511T2 (https=)
MX (1) MX2022007846A (https=)
PE (1) PE20221584A1 (https=)
PH (1) PH12022551546A1 (https=)
PL (1) PL4081511T4 (https=)
RS (1) RS66019B1 (https=)
SI (1) SI4081511T1 (https=)
TW (1) TWI891696B (https=)
WO (1) WO2021130492A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013299A (es) 2019-04-30 2022-01-31 Sitryx Therapeutics Ltd Derivados de acido itaconico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable.
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
EP4192821A1 (en) 2020-08-05 2023-06-14 Sitryx Therapeutics Limited Alpha,beta unsaturated methacrylic esters with anti-inflammatory properties
EP4330231A1 (en) * 2021-04-26 2024-03-06 Sitryx Therapeutics Limited 2-methylene-4-oxo-butanoic acid drivatives for the treatment of inflammation
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を治療するための方法
EP4359390A1 (en) * 2021-06-22 2024-05-01 Sitryx Therapeutics Limited Acrylamide derivatives useful as anti-inflammatory agents
CN113499453B (zh) * 2021-07-20 2022-10-21 徐州医科大学 自噬抑制及抗炎联合温合光热诊疗剂及其制备方法与应用
US20240360067A1 (en) 2021-08-11 2024-10-31 Sitryx Therapeutics Limited Derivatives of itaconic acid and their use as anti-inflammatory agents
AU2023287566A1 (en) 2022-06-22 2025-01-16 Sitryx Therapeutics Limited Oxadiazole derivatives, preparation process thereof and their use in treating inflammatory diseases
WO2024089421A1 (en) 2022-10-25 2024-05-02 Sitryx Therapeutics Limited Tetrazole derivatives
CN120712258A (zh) 2022-12-15 2025-09-26 西特瑞治疗有限公司 用于治疗或预防炎性疾病或与不良免疫反应相关的疾病的取代吡啶类化合物
KR102864655B1 (ko) * 2023-01-19 2025-09-29 대한민국 뎅기바이러스 감염에 의한 질환의 예방 또는 치료용 약학적 조성물
CN115819186B (zh) * 2023-02-14 2023-05-16 广东银珠医药科技有限公司 一种3,5-二氯苯甲醇的新型制备方法
CN117205194A (zh) * 2023-05-10 2023-12-12 苏州大学 衣康酸或其衍生物在制备预防或治疗急性移植物抗宿主病药物中的应用
CN116725998A (zh) * 2023-07-20 2023-09-12 中国科学技术大学 特立氟胺在抑制nlrp3炎症小体活化中的应用
CN119792264B (zh) * 2025-03-14 2025-06-10 华中科技大学同济医学院附属同济医院 丁酰肼在制备预防或治疗copd的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011235A1 (en) * 1993-10-20 1995-04-27 The Upjohn Company Pyrimidinones as antiarthritic and anti-inflammatories
US6566384B1 (en) * 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
KR101861883B1 (ko) * 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
WO2014152263A1 (en) * 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
AU2014290368B2 (en) * 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
CN103923105B (zh) * 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
EP3416634A4 (en) 2016-02-15 2019-10-09 Artyomov, Maxim IMMUNOMODULATORY AGENTS AND METHOD FOR USE THEREOF
WO2019036509A1 (en) 2017-08-14 2019-02-21 Washington University METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH CANCER, INFLAMMATION OR IMMUNE RESPONSE
CN110731955B (zh) 2019-10-28 2023-05-02 中山大学 衣康酸二甲酯在预防和治疗溃疡性结肠炎及其癌变中的应用

Also Published As

Publication number Publication date
JP2025131581A (ja) 2025-09-09
TWI891696B (zh) 2025-08-01
EP4081511A1 (en) 2022-11-02
SI4081511T1 (sl) 2024-12-31
PH12022551546A1 (en) 2023-05-03
CL2022001722A1 (es) 2023-03-03
EP4442319A3 (en) 2025-01-15
MX2022007846A (es) 2022-07-19
EP4081511B3 (en) 2026-03-04
US20230219907A1 (en) 2023-07-13
CR20220300A (es) 2022-08-23
MA58170B1 (fr) 2024-10-31
MD4081511T2 (ro) 2025-01-31
CA3161424C (en) 2025-10-21
AU2020412853A1 (en) 2022-05-26
IL293982A (en) 2022-08-01
EP4442319A2 (en) 2024-10-09
HRP20241378T1 (hr) 2025-01-03
CA3161424A1 (en) 2021-07-01
WO2021130492A1 (en) 2021-07-01
KR20220119425A (ko) 2022-08-29
RS66019B1 (sr) 2024-11-29
DK4081511T3 (da) 2024-09-23
PL4081511T4 (pl) 2024-12-09
CN115066418A (zh) 2022-09-16
IL293982B1 (en) 2025-04-01
JP2023508142A (ja) 2023-03-01
ES2987014T3 (es) 2024-11-13
JP7679384B2 (ja) 2025-05-19
BR112022011933A2 (pt) 2022-09-06
JOP20220162A1 (ar) 2023-01-30
LT4081511T (lt) 2024-10-25
HUE068571T2 (hu) 2025-01-28
ECSP22049370A (es) 2022-07-29
EP4081511B1 (en) 2024-07-31
CA3280359A1 (en) 2026-03-02
PL4081511T3 (pl) 2024-11-25
FI4081511T3 (fi) 2024-10-24
IL293982B2 (en) 2025-08-01
PE20221584A1 (es) 2022-10-06
CN115066418B (zh) 2025-09-05
TW202138356A (zh) 2021-10-16

Similar Documents

Publication Publication Date Title
CO2022008652A2 (es) Derivados carboxi con propiedades antiinflamatorias
ECSP21086530A (es) Derivados de ácido itacónico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable
CY1125110T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
EA201691194A1 (ru) Стимуляторы ргц
CU20150119A7 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
MX2022007801A (es) Formas polimorficas de rad1901-2hcl.
MX381911B (es) Derivados heterociclicos y uso de los mismos.
MX384244B (es) 4-fenilpiperidinas sustituidas, su preparacion y uso.
MX383975B (es) Derivado de anillo fusionado como inhibidor del receptor a2a
CR20160133A (es) Derivados de fenilalanina sustituidos
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
MX379437B (es) Derivados de hidrazina-bencilo sustituidos, como inhibidores de ppp1r15a y ppp1r15b, y el uso de los mismos para el tratamiento de trastorno de proteostasis.
CL2019000487A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana.
BR112022011147A2 (pt) Compostos para inibir fatores de neovascularização e uso dos mesmos
BR112021018357A2 (pt) Forma cristalina de inibidor de fosfodiesterase, método de preparação para a mesma e uso da mesma
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
MX2019002166A (es) Agonistas del receptor cxcr3.
EA201692371A1 (ru) 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений
EA201892585A1 (ru) 6-(БУТА-1,3-ДИИН-1-ИЛ)БЕНЗО[d]ТИАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ
DOP2016000062A (es) Derivados de indol-urea de glucopiranosil sustituido y su uso como inhibidores de sglt
CO2019011285A2 (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.